This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2025 Remove Coronary Artery Disease Remove Peripheral Arterial Disease
article thumbnail

Johnson and Johnson Completes Acquisition of Shockwave Medical

DAIC

MAY 31, 2024

This transaction further extends Johnson & Johnson MedTech’s leadership in cardiovascular intervention. Johnson & Johnson expects the transaction to be accretive to operating margin, but considering the impact of financing costs, is expected to dilute adjusted earnings per share by approximately $0.10 in 2024 and approximately $0.17

Peripheral Arterial Disease 104
Peripheral Arterial Disease Innovation Coronary Artery Disease Cardiovascular Interventions 104
article thumbnail

Johnson and Johnson to Acquire Shockwave Medical

DAIC

APRIL 5, 2024

With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary artery disease (CAD) and peripheral artery disease (PAD). in 2024 and approximately $0.17

Cardiovascular Interventions 105
Cardiovascular Interventions Technology Innovation Angina 105
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join thousands of Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024